Corcept Therapeutics, based in Menlo Park, California, is a commercial-stage pharmaceutical company that markets Korlym for Cushing's syndrome and has a portfolio of selective cortisol modulators. Founded in 2004, it employs 352 people and offers around 1,000 compounds.
Sean Maduck sold 20,000 shares of CORT on 2 June at $80.77 per share, worth a total of $1.6M. They now own 31,953 CORT shares, or a 53% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
